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ABSTRACT The cellular targets for estramustine, an
antitumor drug used in the treatment of hormone-refractory
prostate cancer, are believed to be the spindle microtubules
responsible for chromosome separation at mitosis. Estramus-
tine only weakly inhibits polymerization of purified tubulin
into microtubules by binding to tubulin (Kd, '30 mM) at a site
distinct from the colchicine or the vinblastine binding sites.
However, by video microscopy, we find that estramustine
strongly stabilizes growing and shortening dynamics at plus
ends of bovine brain microtubules devoid of microtubule-
associated proteins at concentrations substantially below
those required to inhibit polymerization of the microtubules.
Estramustine strongly reduced the rate and extent both of
shortening and growing, increased the percentage of time the
microtubules spent in an attenuated state, neither growing
nor shortening detectably, and reduced the overall dynamicity
of the microtubules. Significantly, the combined suppressive
effects of vinblastine and estramustine on the rate and extent
of shortening and dynamicity were additive. Thus, like the
antimitotic mechanisms of action of the antitumor drugs
vinblastine and taxol, the antimitotic mechanism of action of
estramustine may be due to kinetic stabilization of spindle
microtubule dynamics. The results may explain the mecha-
nistic basis for the benefit derived from combined use of
estramustine with vinblastine or taxol, two other drugs that
target microtubules, in the treatment of hormone-refractory
prostate cancer.
Estramustine (EM) is a chemotherapeutic drug used for the
treatment of advanced prostate carcinoma (1–5). EM inhibits
growth and induces mitotic arrest in many cultured cells,
including the human prostate carcinoma cell lines DU 145 and
PC3 (6–8). EM disrupts interphase and mitotic microtubule
networks in cells (5–10) and an EM-resistant prostate carci-
noma cell line has been shown to have a higher level of
expressed bIII and bIV tubulin isotypes than EM-sensitive
cells (11, 12). Whereas EM is known to bind to certain other
proteins, including a secretory protein that is thought to
facilitate EM accumulation in tumor cells called the estramus-
tine-binding protein (13, 14) and the the P-glycoprotein efflux
pump (15), results of most studies indicate that microtubules
are the drug’s principal cellular target.
However, the mechanism by which EM affects microtubule
organization and function in cells has remained unclear. The
clinically used form of EM is the prodrug, EM phosphate
(EMP), which is rapidly dephosphorylated to produce EM in
the body (16). EMP is not active in cells because it cannot
penetrate the plasma membrane. However, EMP is active in
vitro and weakly inhibits polymerization and induces depoly-
merization of microtubule-associated protein (MAP)-
containing microtubules (17–23). Fifty percent inhibition of
MAP-containing microtubule polymerization in vitro occurs at
an EMP concentration of '100 mM (21). EMP also has been
shown to bind weakly to brain MAPs (between 2 and 20 sites
per MAP molecule) with a binding constant of '15–20 mM
(21, 23). EM has also been shown to bind weakly to MAPs and
to inhibit microtubule polymerization in vitro (3, 24). Based
upon these and other related findings, the antimitotic mech-
anism of action of EM was thought to be due to a unique action
on MAPs (19, 21–24).
However, results of other studies have not been consistent
with the idea that EM acts on MAPs. Recent studies have
shown that EM binds to tubulin (kd '23 mM; refs. 11 and 25)
and that it has different affinities for tubulins composed of
specific b-tubulin isotypes (11). In addition, it weakly inhibits
polymerization and induces depolymerization of MAP-free
microtubules in vitro (9). In the same work, EM did not remove
MAPs from taxol-stabilized microtubules and in other studies
it had no effect on the binding of MAPs to microtubules (21)
or to microfilaments (26). These studies indicate that EM may
act on microtubules through an interaction with tubulin.
Microtubules are intrinsically dynamic polymers and con-
siderable evidence now indicates that the dynamics of mitotic
spindle microtubules, not just their presence, are critically
required for proper spindle function (27–29). Both in vitro and
in cells microtubule ends switch between growing and short-
ening states (called dynamic instability), due to a stochastic
gain and loss at the microtubule ends of a stabilizing GTP or
GDPzPi cap (30–34). Also, at steady state, microtubules can
grow predominantly at one end and shorten at the opposite
end, a dynamic behavior termed treadmilling (35, 36). Ex-
tremely rapid microtubule dynamics during mitosis appear to
be essential for building the mitotic spindle and for the
complex movements of the chromosomes (29, 37, 38).
Microtubules are the targets for a large number of antimi-
totic agents including the antitumor drugs taxol and vinblas-
tine. Most such agents either inhibit or promote microtubule
polymerization and, at appropriately high concentrations, they
either increase or decrease the spindle microtubule mass. For
example, vinblastine and colchicine depolymerize spindle mi-
crotubules, whereas taxol increases spindle microtubule mass
(38–40). However, we have recently found that while these and
a number of other antimitotic drugs affect the microtubule
polymer mass at relatively high drug concentrations, they all
strongly suppress the dynamics of microtubules in the absence
of significant effects on polymer mass at relatively low con-
centrations (40–46).
In this study we show that high concentrations of EM inhibit
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vitro, in confirmation of the work of Dahllof et al. (9). However,
at steady-state in vitro at EM concentrations that did not
appreciably affect the microtubule polymer mass, the drug
strongly stabilized the dynamics of the microtubules. The
results indicate that, like taxol and vinblastine, EM may exert
its antiproliferative effects by stabilizing spindle microtubule
dynamics through a novel interaction with tubulin.
MATERIALS AND METHODS
Purification of Tubulin. Microtubule protein (tubulin plus
MAPs) was isolated from bovine brain by three cycles of
polymerization and depolymerization (45). Tubulin devoid of
detectable MAPs by Coomassie staining on SDS gels was
obtained by phosphocellulose chromatography. The tubulin
solution was quickly frozen as drops in liquid nitrogen and
stored at 270°C until used. Protein concentration was deter-
mined by the method of Bradford (47) using BSA as the
standard.
Determination of Steady-State Microtubule Polymer Mass.
In all experiments, tubulin pellets were thawed and centrifuged
at 4°C to remove any aggregated or denatured tubulin. Tubulin
(13 mM) was mixed with Strongylocentratus purpuratus f lagellar
axonemal seeds in 87 mM 1–4 piperazinediethanesulfonic acid
(Pipes), 36 mM 2-morpholinoethanesulfonic acid (Mes), 1.8
mM MgCl2, 1 mM EGTA (pH 6.8) (PMME buffer) containing
1.5 mM GTP and incubated at 37°C for 35–45 min to attain
steady state (48). The microtubules were sedimented by cen-
trifugation (150,000 3 g for 1 hr) and microtubule pellets were
solubilized in PMME buffer at 0°C for protein determination.
Determination of Microtubule Dynamics by Video Micros-
copy. Tubulin (13 mM) was polymerized to steady state onto
flagellar seeds in the absence or presence of EM (a gift from
Beryl Hartley-Asp, Pharmacia, Lund, Sweden). The seed
concentration was adjusted to achieve 3–6 seeds per micro-
scope field. After 35 min of incubation, samples of microtubule
suspensions (4 ml) were prepared for video microscopy and the
dynamics of individual microtubules were recorded at 37°C
and analyzed as described (48). The microtubules were ob-
served for a maximum of 45 min after they had reached steady
state. We considered a microtubule to be in a growth phase if
it increased in length by .0.2 mm at a rate .0.15 mmymin, and
in a shortening phase if it shortened in length by .0.2 mm at
a rate .0.3 mmymin. Microtubules undergoing length changes
equal to or less than 0.2 mm over the duration of six data points
were considered to be in an attenuated state. The same tubulin
preparation was used for all experiments; 20–30 microtubules
were analyzed for each experimental condition.
The catastrophe frequency [a catastrophe is a transition
from the growing or attenuated state to shortening (32)] was
determined by dividing the number of catastrophes by the sum
of the total time spent in the growing plus attenuated states for
all microtubules for a particular condition. The rescue fre-
quency [a rescue is a transition from shortening to growing or
attenuation, excluding new growth from a seed (32)] was
calculated by dividing the total number of rescue events by the
total time spent shortening for all microtubules for a particular
condition. Dynamicity is the sum of all growing and shortening
events divided by the total time measured, including time spent
in the attenuated state.
Vinblastine and Colchicine Binding. Binding of vinblastine
to tubulin was measured by a column centrifugation method.
Tubulin (5 mM) and vinblastine (6 mM) containing trace
amounts of [3H]vinblastine (Amersham; specific activity 11
Ciymmol; 1 Ci 5 37 GBq) were incubated with or without EM
(0–50 mM) in PEM buffer (50 mM Pipesy0.18 mM MgCl2y1
mM EGTA, pH 6.8) at 34°C for 15 min, and 90 ml was
centrifuged through 1-ml columns of Biogel P6 (Bio-Rad)
equilibrated in the same buffer. Radioactivity and protein in
the eluates were then determined. Background radioactivity,
measured in the absence of tubulin, was #1% of the experi-
mental values. The stoichiometry of vinblastine binding to
tubulin controls was 0.65 6 0.03 mol vinblastine per mol
tubulin. Data are the average of two experiments and each
experiment was carried out in duplicate. For colchicine bind-
ing, tubulin (3.6 mM) and EM (0–50 mM) were incubated for
20 min at 34°C, after which 5 mM colchicine containing trace
amounts of [3H]colchicine (New England Nuclear; specific
activity 1.03 Ciymol) was added and incubation continued for
an additional hour. Colchicine binding was determined by a
DE-81 filter paper assay (49). The stoichiometry of colchicine
binding to tubulin controls was 0.80 6 0.04 mol colchicine per
mol tubulin. Experiments were performed three times.
Fluorescence Measurements. Fluorescence measurements
were performed using a Perkin–Elmer LS50B spectrofluorom-
eter. Spectra were taken by multiple scans and buffer blanks
were subtracted from all measurements. The inner filter effects
were corrected as described by Sackett (50) and empirically by
measuring the change of fluorescence intensity of a tryptophan
solution equivalent to the tubulin concentration in the pres-
ence of EM (51). EM did not quench the fluorescence of
tryptophan in solution after inner filter effect correction. The
excitation and emission wavelengths were 295 nm and 336 nm,
respectively. The fraction of binding sites (b) occupied by EM
was determined using the following relationship: b 5 (Fo 2
F)y(Fo 2 Fm), where Fo is the fluorescence intensity of tubulin
in the absence of EM, F is the corrected fluorescence intensity
when the tubulin and EM are in equilibrium, and Fm is the
calculated fluorescence intensity of the fully liganded tubulin.
Fm was determined by plotting 1y(Fo 2 F) versus 1yL (L 5
total ligand concentration) and extrapolating 1yL 5 0. The
association constant, Ka, was determined using the relation-
ship: Ka 5 (by1 2 b) 3 1yLf, where Lf 5 L 2 b [C] and [C]
is the molar concentration of ligand binding sites assuming a
single binding site per tubulin dimer.
RESULTS
Inhibition of Microtubule Polymerization by EM. We first
analyzed the ability of EM to inhibit polymerization of phos-
phocellulose purified (MAP-free) tubulin into microtubules in
vitro. Polymerization was initiated by adding the tubulin to
axoneme seeds, and at steady state the polymer was sedi-
mented and quantitated (see Materials and Methods). EM
inhibited microtubule polymerization in a concentration-
dependent manner but relatively weakly; only 18% inhibition
occurred at 20 mM EM (Fig. 1). The results confirm that EM
inhibits the polymerization of MAP-free tubulin into micro-
tubules with low potency (9).
FIG. 1. Effects of EM on steady-state microtubule polymer mass.
Tubulin (13 mM) was polymerized to steady state onto the ends of
flagellar seeds by incubation at 37°C for 35 min in the absence or
presence of different EM concentrations. The microtubule polymer
mass was determined as described in Materials and Methods. Data are
from five independent experiments. (Error bars 5 SEM.)
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Stabilization of Microtubule Dynamics by EM. To deter-
mine whether concentrations of EM that minimally inhibit
microtubule polymerization could stabilize microtubule dy-
namics, we initially determined the number of microtubules on
axonemes by video microscopy before and 15 min after 3-fold
dilution in PMME buffer, in both the presence and absence of
20 mM EM. Prior to dilution, 100% of the axonemes contained
at least one relatively long microtubule (5–12 mm in length).
After dilution, only 8% of control axonemes (a total of 177
axoneme constructs) contained a short microtubule (#2 mm in
length), whereas 20% of the axonemes (a total of 123 axoneme
constructs) incubated with EM contained a short microtubule.
Thus, EM appeared to stabilize microtubules against dilution-
induced disassembly.
Based on the aforementioned results, we then analyzed the
effects of EM on the dynamics of individual microtubules at
steady state by video microscopy. Under the experimental
conditions used, microtubule growth occurred predominantly
at the plus ends of the seeds as determined by the growth rates,
the number of microtubules that grew, and the relative lengths
of the microtubules at the opposite ends of the seeds (32, 45,
46, 52–54). Several life history traces of length changes at the
plus ends of individual microtubules with time in the absence
of EM are shown in Fig. 2A. As previously documented, the
microtubules predominantly alternated between phases of
growing and shortening, but also spent a small fraction of time
in an attenuated state, neither growing nor shortening detect-
ably (43–46, 52–55). Addition of EM suppressed dynamics; 20
mM of EM visibly reduced the growing and shortening rates
and increased the percentage of time that the microtubules
spent in the attenuated state (Fig. 2B).
The actions of EM on the individual dynamic instability
parameters were determined quantitatively (Table 1). EM
strongly suppressed the rate and extent of shortening and growing
in a concentration-dependent manner. EM (20 mM) reduced the
shortening rate by 51% and the mean length shortened per
shortening event by 46% (Table 1; Fig. 3). EM (5 mM) reduced
the growing rate by 27% and at the highest concentration studied
(50 mM) EM reduced the mean growing rate by 45%. The
average length that the microtubules grew per growing event was
also strongly decreased by EM (Fig. 3). For example, the mean
length grown was reduced by 45% at 20 mM EM.
The transition frequencies among the growing, shortening,
and attenuated states, which may reflect the gain and loss of
the stabilizing tubulin–GTP or tubulin–GDP–Pi cap at micro-
tubule ends, are considered to be important in the regulation
of microtubule dynamics in cells (55, 56). EM had no signif-
icant effect on the catastrophe frequency and only increased
the rescue frequency 1.7-fold at the highest EM concentration
examined (Table 1). Thus, EM may not affect the mechanism
governing the gain and loss of the stabilizing cap.
At or near steady state, both in vitro and in cells, microtu-
bules spend a considerable fraction of time in an attenuated or
pause phase (43–46, 52–55). EM strongly decreased the frac-
tion of time the microtubules spent growing and increased the
percentage of time that the microtubules spent in the atten-
uated state (Table 1). For example, 20 mM EM increased the
percentage of time spent in the attenuated phase 7.5-fold
(Table 1). Dynamicity is a measure of the overall visually
detectable growth and shortening at a microtubule end (44–
46). EM suppressed dynamicity in a concentration dependent
manner (Table 1); 5 mM EM suppressed dynamicity by 23%
and 20 mM EM reduced the dynamicity by 61%.
Interaction of EM with Tubulin. We found that EM
quenched the intrinsic f luorescence of tubulin in a concentra-
tion-dependent manner (Fig. 4). The binding constant deter-
mined from the data was 30 6 9 mM (Fig. 4 Inset), a value
consistent with previous data (11, 25). These data also indicate
that the binding of EM to tubulin induces a conformational
change in tubulin. Additional evidence indicating that EM
binding to tubulin induces a conformational change in tubulin
is that EM increased the fluorescence of bis (8-anilinonaph-
thalene 1-sulfonate) when bound to tubulin (data not shown).
The colchicine and vinblastine binding domains are two
important drug binding regions in soluble tubulin (39). In this
study we found that EM does not appear to bind to the
colchicine domain. When added prior to the addition of
colchicine, 30 mM and 50 mM EM inhibited colchicine binding
by only 7% and 9%, respectively, and when colchicine was
added prior to or simultaneously with EM, EM has no
detectable effect on the binding of colchicine to tubulin.
Tubulin (5 mM) was also incubated with 6 mM [3H]vinblastine
in the absence or presence of EM (5–50 mM) and the amount
of vinblastine bound to tubulin was determined (see Materials
and Methods). EM had no detectable effect on the binding of
vinblastine to tubulin at the concentrations examined and,
thus, EM also does not appear to bind to the vinca alkaloid
binding domain. Laing et al. (11) recently obtained similar
evidence indicating that EM does not bind either to the
colchicine or vinblastine binding domains. Thus, vinblastine,
colchicine, and EM stabilize microtubule dynamics by binding
to tubulin at distinct sites.
The Combined Suppressive Effects of EM and Vinblastine
on Dynamics. EM is used clinically in combination with
vinblastine for the treatment of hormone-refractory prostate
cancer (1, 4). Whereas the potency of vinblastine is consider-
ably greater than that of EM, it is interesting to note that
vinblastine stabilizes microtubule dynamics in a manner some-
what, but not entirely, similar to that of EM (Table 1, Fig. 3)
(44, 45, 52). Because vinblastine and EM stabilize dynamics by
binding to different sites in tubulin, we wanted to determine
whether the stabilizing effects of the two drugs when present
simultaneously might be additive or possibly synergistic. We
used 10 mM EM, which by itself decreased dynamicity '1.5-
fold, and 50 nM vinblastine, which by itself decreased dyna-
micity '2.1-fold (Table 1, see also ref. 52). The two drugs
together reduced dynamicity 4.8-fold, indicating that the com-
bined suppressive effect of vinblastine and EM on dynamicity
is greater than additive (Table 2). Similarly, EM and vinblas-
FIG. 2. Growing and shortening length changes of microtubules at
plus ends at steady state in the absence (A) and presence of 20 mM EM
(B). Lengths of individual microtubules were measured as described
in Materials and Methods.
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tine together produced greater than additive suppression of
the shortening rate and not quite additive but significantly
increased suppression of the growing rate (Table 1).
DISCUSSION
In this study we found that EM stabilized microtubule dynam-
ics. EM exerted its strongest suppressive effects on the rate and
extent of shortening and growing and the percentage of total
time that the microtubules spent growing (Table 1). Interest-
ingly, the ability of EM to inhibit microtubule polymerization
was relatively weak (Fig. 1; ref. 9) compared with its ability to
stabilize microtubule dynamics (Fig. 1, Table 1). Similar
results, but not as striking as those reported here with EM,
have also been observed with vinblastine (52) and colchicine
(53). We also found that EM bound to tubulin at a site distinct
from those of colchicine and vinblastine and that EM and
vinblastine exerted additive suppressive effects on dynamics.
It is not known whether EM acts at microtubule ends like
vinblastine or whether it binds to the microtubule surface like
taxol. Because EM reduces the growing rate, EM could be acting
at microtubule ends. If so, its mechanism might involve steric
hindrance or alteration of the microtubule lattice at the end in a
way that makes tubulin incorporation energetically unfavorable.
Because EM induces a conformational change in tubulin (Fig. 4),
binding of EM to tubulin at the end of the microtubule could
reduce the rate of shortening by inducing a conformational
change in the microtubule lattice that increases tubulin–tubulin
interactions in a manner proposed for vinblastine.
Interestingly, EM did not significantly reduce the catastro-
phe frequency, an action one might expect for a drug that acts
at microtubule ends (Table 1). Because catastrophes may
involve loss of the stabilizing tubulin–GTP-Pi or tubulin–GTP
cap at the microtubule end, it is possible that EM does not act
at the extreme end of the microtubule, but rather that it binds
to the microtubule surface. Similar to the mechanism of action
of taxol (54) the presence of few EM molecules bound at the
surface of a microtubule near an end could alter the tubulin
lattice in a way that stabilizes dynamics. However, a mecha-
nism involving the binding of EM to the microtubule surface
cannot easily account for the fact that EM inhibits microtubule
growth. A possibility consistent with the low potency of EM is
that it binds to the end of the microtubule, but weakly or
transiently in a way that does not affect the frequency of cap
loss but does reduce the growing rate.
EM appears to bind to a novel binding site in tubulin.
However, despite the differences in the molecular sites of
action, EM, colchicine, vinblastine, and taxol all stabilize
microtubule dynamics at low concentrations without signifi-
cantly altering the microtubule polymer mass (43–45, 53, 54).
These findings support the hypothesis that the action of these
agents responsible for the most potent antimitotic and anti-
proliferative activities and for the killing of tumor cells may be
the kinetic stabilization of spindle microtubule dynamics (38).
EM in combination with vinblastine exerts synergistic cytotox-
icity (14, 57) indicating that antimitotic agents that act on
FIG. 3. Microtubule length changes per growing (circles) or short-
ening (squares) event as a function of EM concentration. The average
length microtubules grew during growing events was determined by
dividing the summed growing lengths for all microtubules for a
particular condition by the total number of growing events measured
for that condition. The mean shortening length per shortening event
was determined similarly. (Error bars 5 SEM.)
FIG. 4. Effects of EM on tubulin fluorescence. Tubulin (5 mM) was
incubated in the absence (solid line) or presence of 5 mM (— —), 10
mM (zzzz), 15 mM (— - —), 20 mM (- - - -), and 25 mM (— - - —) EM
at 25°C for 20 min and the fluorescence determined as described in
Materials and Methods. Data in the Inset are representative of four
replicate experiments.
Table 1. Effects of EM alone and EM combined with vinblastine on dynamics
No vinblastine 0.05 mM vinblastine
0 mM
EM
5 mM
EM
10 mM
EM
20 mM
EM
50 mM
EM
0 mM
EM
10 mM
EM
Rate (mm/min)
Growing 1.25 6 0.5 0.91 6 0.7 0.86 6 0.5 0.81 6 0.4 0.69 6 0.4 0.69 6 0.6 0.55 6 0.4
Shortening 16.7 6 5.5 16.8 6 6.8 12.6 6 8.1 8.2 6 5.8 6.8 6 5.6 7.3 6 5.6 3.4 6 3.0
Percent time in phase
Growing 83.8 75.2 68.6 60.0 59.0 61.0 48.0
Shortening 12.2 10.1 11.5 9.2 11.8 14.5 11.7
Attenuation 4.0 14.7 19.9 30.8 29.2 24.5 40.3
Transition frequencies (min21)
Catastrophe 0.34 6 0.06 0.28 6 0.07 0.37 6 0.06 0.20 6 0.05 0.26 6 0.05 0.28 6 0.06 0.28 6 0.06
Rescue 0.85 6 0.24 1.34 6 0.44 2.06 6 0.40 1.61 6 0.36 1.47 6 0.29 1.6 6 0.40 2.1 6 0.50
Dynamicity (dimer/sec) 87 67 57 35 34 41 18
Valves are 6 SD.
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microtubules can exert additive or synergistic effects. Recent
clinical trials have indicated that combinations of EM and vin-
blastine and EM and paclitaxel are significantly more effective in
patients with advanced prostate cancer than EM alone (1, 4, 58).
Vinblastine and EM have very different dose-limiting toxicities
and the original basis for combining EM with vinblastine was the
idea that increased antitumor activity might be obtained in
conjunction with decreased toxicity because vinblastine acts on
tubulin and EM was thought to act on MAPs (1, 4). However, EM
appears to act by binding to tubulin and stabilizing microtubule
dynamics. The finding described here that EM in combination
with vinblastine exerted suppressive effects on microtubule dy-
namics that were stronger than their individual additive effects
may provide a mechanistic explanation for the improved re-
sponses reported for combination therapy as compared with
monotherapy. The combined use of drugs that act by stabilizing
microtubule dynamics by different mechanisms could result in
increased antitumor activity without some of the specific harmful
side-effects of the individual drugs by minimizing the dose of the
individual drugs. It would be highly desirable to explore the
clinical use of combinations of such antimitotic drugs in other
tumor types sensitive to microtubule-stabilizing drugs.
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